Ji Dongmei

2 clinical trials · Sponsor

Record	Firm	Date
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC (NCT07509099)	Ji Dongmei	2026-04-01
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study (NCT07464366)	Ji Dongmei	2026-03-19

Every clearance here is in the API, with alerts when new ones post.